Research analysts covering AVANT TECHNOLOGIES.
Recent press releases and 8-K filings for AVAI.
Avant Technologies Inc. Forms Joint Venture Insulinova, Inc. with Austrianova
AVAI
New Projects/Investments
M&A
- Avant Technologies Inc. (AVAI) and SGAustria Pte. Ltd. (Austrianova) entered into a Joint Venture and License Agreement, effective November 1, 2025, to form a new joint venture named Insulinova, Inc.. This agreement supersedes a previous one from September 19, 2025, which was retracted.
- The ownership of Insulinova will be split 50% AVAI and 50% Austrianova.
- AVAI will contribute up to $1.5 million USD in capital for Insulinova's formation and operation over the next 18 months, while Austrianova will contribute its proprietary cell encapsulation technology and intellectual property.
- Additionally, AVAI has agreed to provide an $8.5 million follow-up financing to Insulinova in the form of a loan for further development and clinical testing.
Nov 4, 2025, 12:22 PM
Avant Technologies and Austrianova Launch Klothonova Joint Venture for Age-Related Cellular Therapies
AVAI
Product Launch
New Projects/Investments
- Avant Technologies Inc. (AVAI) and global biotechnology firm Austrianova have launched Klothonova LLC, a joint venture focused on developing cell-based therapies to combat age-related diseases and advance anti-aging treatments.
- Klothonova's program aims to engineer a genetically modified cell line that overexpresses the Klotho protein, utilizing Austrianova's proprietary cell-encapsulation technology.
- Initial R&D proof of concept studies have successfully demonstrated the feasibility of using encapsulated cells to continuously produce the Klotho protein.
- The next phase involves preparing a GMP grade human cell clone for preclinical and clinical studies, with Austrianova conducting requalification of its ISO9001:2015 compliant GMP facility.
Oct 21, 2025, 12:00 PM
Avant Technologies Announces Strategic Shift to Biotech Partnerships
AVAI
New Projects/Investments
- Avant Technologies Inc. announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing agreements to advance treatments for chronic and age-related conditions.
- This new model focuses on collaborative biotech innovation, identifying promising cell lines and forging alliances with leading biotech companies, scientists, and clinicians.
- Key areas of focus for these collaborations include diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, and kidney disease.
- The company has applied for a corporate name change to better reflect its focus on pioneering biotechnology collaborations.
- Avant's first joint venture is with Ainnova Tech, Inc., for AI-driven diagnostics, and a recent joint venture focuses on developing a cell line therapy that produces the Klotho protein.
Sep 25, 2025, 12:00 PM
Avant Technologies Forms Joint Venture for Diabetes Treatment
AVAI
New Projects/Investments
M&A
- Avant Technologies (OTCQB: AVAI), Art-Islets Pte. Ltd., and Austrianova (SGAustria Pte. Ltd.) have formed a Joint Venture and License Agreement to revolutionize diabetes treatment through innovative stem cell and encapsulation technologies.
- The collaboration aims to research, develop, manufacture, and commercialize advanced therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide.
- Avant Technologies will provide initial funding over the next eight months to achieve the first three milestones and will leverage its resources to secure further funding for a potential Phase 1 clinical trial.
- Art-Islets contributes its proprietary "differentiation system" for transforming ESCs into insulin-producing cells, and Austrianova provides its proprietary cell-encapsulation technology.
Sep 24, 2025, 12:30 PM
Avant Technologies and Austrianova Form Joint Venture for Klotho-Based Therapies
AVAI
New Projects/Investments
M&A
- Avant Technologies Inc. (OTCQB: AVAI) and Austrianova have established Klothonova, Inc., a new Nevada corporation, as a 50/50 joint venture through a Joint Venture and License Agreement.
- Klothonova will focus on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion.
- Austrianova will contribute its proprietary cell encapsulation technology, intellectual property, and 'know-how', while Avant Technologies will provide capital and additional resources to support Klothonova's operations.
Sep 18, 2025, 12:30 PM
AVANT TECHNOLOGIES INC. Forms Joint Venture Klothonova with Austrianova
AVAI
New Projects/Investments
M&A
- AVANT TECHNOLOGIES INC. (AVAI) and SGAustria Pte. Ltd. (Austrianova) entered into a Joint Venture & License Agreement on September 15, 2025, to establish a new Nevada Corporation named Klothonova, Inc..
- Klothonova's primary objective is to develop, maintain, and support treatments for various medical conditions, including Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions, by utilizing encapsulated Klotho-producing cells.
- AVAI will contribute up to $1.5 million USD in capital for Klothonova's formation and operation over the next eighteen months, with the potential for an additional $8.5 million USD in follow-up financing as a loan.
- The ownership of Klothonova will be equally split, with 50% held by AVAI and 50% by Austrianova, each possessing 1,500,000 shares of common stock.
- Austrianova will grant an exclusive license for its proprietary cell encapsulation technology to Klothonova for the development of these treatments.
Sep 18, 2025, 11:10 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more